175 359

Cited 124 times in

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.

DC FieldValueLanguage
dc.contributor.author이준상-
dc.contributor.author구자승-
dc.contributor.author김승일-
dc.contributor.author박병우-
dc.contributor.author박세호-
dc.contributor.author박형석-
dc.contributor.author이종석-
dc.date.accessioned2014-12-20T16:54:20Z-
dc.date.available2014-12-20T16:54:20Z-
dc.date.issued2011-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93601-
dc.description.abstractBACKGROUND: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. PATIENTS AND METHODS: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. RESULTS: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. CONCLUSIONS: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1755~1762-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHBiomarkers, Tumor/metabolism*-
dc.subject.MESHBreast Neoplasms/metabolism*-
dc.subject.MESHBreast Neoplasms/mortality*-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHReceptor, ErbB-2/metabolism-
dc.subject.MESHReceptors, Androgen/metabolism*-
dc.subject.MESHReceptors, Estrogen/metabolism-
dc.subject.MESHTissue Array Analysis-
dc.subject.MESHTreatment Outcome-
dc.titleAndrogen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorS. Park-
dc.contributor.googleauthorJ. S. Koo-
dc.contributor.googleauthorM. S. Kim-
dc.contributor.googleauthorH. S. Park-
dc.contributor.googleauthorJ. S. Lee-
dc.contributor.googleauthorJ. S. Lee-
dc.contributor.googleauthorS. I. Kim-
dc.contributor.googleauthorB.-W. Park-
dc.contributor.googleauthorK. S. Lee-
dc.identifier.doi10.1093/annonc/mdq678-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03143-
dc.contributor.localIdA03175-
dc.contributor.localIdA00198-
dc.contributor.localIdA00658-
dc.contributor.localIdA01475-
dc.contributor.localIdA01524-
dc.contributor.localIdA01753-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.pmid21310761-
dc.subject.keywordandrogen receptor-
dc.subject.keywordbreast cancer-
dc.subject.keywordestrogen receptor-
dc.subject.keywordmolecular apocrine-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameLee, Jun Sang-
dc.contributor.alternativeNameKoo, Ja Seung-
dc.contributor.alternativeNameKim, Seung Il-
dc.contributor.alternativeNamePark, Byeong Woo-
dc.contributor.alternativeNamePark, Se Ho-
dc.contributor.alternativeNamePark, Hyung Seok-
dc.contributor.alternativeNameLee, Jong Seok-
dc.contributor.affiliatedAuthorLee, Jong Seok-
dc.contributor.affiliatedAuthorLee, Jun Sang-
dc.contributor.affiliatedAuthorKoo, Ja Seung-
dc.contributor.affiliatedAuthorKim, Seung Il-
dc.contributor.affiliatedAuthorPark, Byeong Woo-
dc.contributor.affiliatedAuthorPark, Se Ho-
dc.contributor.affiliatedAuthorPark, Hyung Seok-
dc.contributor.affiliatedAuthor구자승-
dc.rights.accessRightsfree-
dc.citation.volume22-
dc.citation.number8-
dc.citation.startPage1755-
dc.citation.endPage1762-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.22(8) : 1755-1762, 2011-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.